INmune Bio Inc.’s $8 Million Initial Public Offering

Sichenzia Ross Ference represented INmune Bio Inc. on the transaction

WestPark Capital, Inc., the Los Angeles based international investment banking firm, executed the initial public offering of 1,020,820 shares of common stock at $8.00 per share for INmune Bio, Inc. (NASDAQ:INMB).

The total offering was $8,166,560. WestPark acted as co-manager for the IPO along with Wallachbeth Capital, LLC. Univest Securities, LLC acted as the lead manager. It marked the first biotech IPO in 2019.

The SRF team was led by Partners Marc Ross (Picture), Thomas Rose and David Manno.

Involved fees earner: David Manno – Sichenzia Ross Ference LLP; Thomas Rose – Sichenzia Ross Ference LLP; Marc Ross – Sichenzia Ross Ference LLP;

Law Firms: Sichenzia Ross Ference LLP;

Clients: INmune Bio Inc. ;

Author: Ambrogio Visconti